| Title: |
Allogeneic Hematopoietic Stem Cell Transplantation for Elderly Acute Lymphoblastic Leukemia Patients: A Registry Study From the Société Francophone de Greffe de Moelle et Thérapie Cellulaire ( SFGM ‐ TC ) ; Allogeneic Hematopoietic Stem Cell Transplantation for Elderly Acute Lymphoblastic Leukemia Patients: A Registry Study From the Société Francophone de Greffe de Moelle et Thérapie Cellulaire (SFGM-TC). |
| Authors: |
Chalandon, Yves; Devillier, Raynier; Boumendil, Ariane; Nguyen, Stephanie; Bulabois, Claude-Eric; Ceballos, Patrice; Brissot, Eolia; Rubio, Marie-Thérèse; Labussière-Wallet, Hélène; Maertens, Johan; Chevallier, Patrice; Maillard, Natacha; Poiré, Xavier; Castilla-Llorente, Cristina; Beguin, Yves; Cornillon, Jérôme; Maury, Sébastien; Marchand, Tony; Daguindau, Etienne; Bay, Jacques-Olivier; Turlure, Pascal; Joris, Magalie; Menard, Anne-Lise; Bilger, Karin; Guillerm, Gaelle; François, Sylvie; Bazarbachi, Ali; Chantepie, Sylvain; Lewalle, Philippe; Marçais, Ambroise; Loschi, Michael; Benakli, Malek; Chauvet, Paul; Forcade, Edouard; Huynh, Anne; Robin, Marie; Masouridi-Levrat, Stavroula |
| Contributors: |
Hôpitaux Universitaires de Genève = University Hospital of Geneva Genève (HUG); Centre de Recherche en Cancérologie de Marseille (CRCM); Aix Marseille Université (AMU)-Institut Paoli-Calmettes (IPC); Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS); Société Francophone de Greffe de Moëlle et de Thérapie Cellulaire = French-speaking Society for Bone Marrow Transplantation and Cell Therapy (SFGM-TC); CHU Pitié-Salpêtrière AP-HP; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU); CHU de Grenoble-Alpes - Centre Hospitalier Universitaire CHU Grenoble (CHUGA); Hôpital Saint Eloi CHU Montpellier; Centre Hospitalier Régional Universitaire Montpellier (CHRU Montpellier); Centre de Recherche Saint-Antoine (CRSA); Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU); Service d'Hématologie CHRU Nancy; Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy); Centre Hospitalier Lyon Sud CHU - HCL (CHLS); Hospices Civils de Lyon (HCL); Universitair Ziekenhuis Leuven = University Hospital of Leuven = Hopital universitaire de Louvain (UZ Leuven); Centre Hospitalier Universitaire de Nantes = Nantes University Hospital (CHU Nantes); Centre hospitalier universitaire de Poitiers = Poitiers University Hospital (CHU de Poitiers La Milétrie ); Cliniques universitaires St Luc Bruxelles; Institut Gustave Roussy (IGR); Centre Hospitalier Universitaire de Liège (CHU-Liège); Institut de Cancérologie et d'Hématologie Universitaire de Saint-Étienne CHU Saint-Etienne (ICHUSE); Centre Hospitalier Universitaire de Saint-Etienne CHU Saint-Etienne (CHU ST-E)-Université Jean Monnet - Saint-Étienne (UJM); CHU Henri Mondor Créteil; Groupe Henri Mondor-Albert Chenevier-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP); Centre Hospitalier Universitaire de Rennes CHU Rennes = Rennes University Hospital Pontchaillou; Microenvironment and B-cells: Immunopathology,Cell Differentiation, and Cancer (MOBIDIC); Université de Rennes (UR)-Établissement Français du Sang Bretagne Rennes (EFS Bretagne - Rennes); Établissement Français du Sang La Plaine Saint-Denis (EFS)-Établissement Français du Sang La Plaine Saint-Denis (EFS)-Institut National de la Santé et de la Recherche Médicale (INSERM); Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon); Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098) (RIGHT); Institut National de la Santé et de la Recherche Médicale (INSERM)-Établissement Français du Sang Bourgogne-Franche-Comté Besançon (EFS BFC - Besançon); Établissement Français du Sang La Plaine Saint-Denis (EFS)-Établissement Français du Sang La Plaine Saint-Denis (EFS)-Université de Franche-Comté (UFC); Université Bourgogne Franche-Comté COMUE (UBFC)-Université Bourgogne Franche-Comté COMUE (UBFC); Service Hématologie Biologique CHU Clermont-Ferrand; CHU Gabriel Montpied Clermont-Ferrand; CHU Clermont-Ferrand-CHU Clermont-Ferrand-CHU Estaing Clermont-Ferrand; CHU Clermont-Ferrand-Pôle Biologie médicale et Anatomie pathologique CHU Clermont-Ferrand; CHU Clermont-Ferrand-CHU Clermont-Ferrand; Service d'Hématologie clinique et thérapie cellulaire CHU Limoges; CHU Limoges; CHU Amiens-Picardie; Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen (CLCC Henri Becquerel); Laboratoire de Génétique Moléculaire CHRU Strasbourg; CHRU Strasbourg; Centre Hospitalier Régional Universitaire de Brest (CHRU Brest); Centre Hospitalier Universitaire d'Angers (CHU Angers); American University of Beirut (AUB); CHU Caen Normandie – Centre Hospitalier Universitaire de Caen Normandie (CHU Caen Normandie); Normandie Université (NU); Hôpital Universitaire de Bruxelles (HUB); M3C-Necker, Hôpital universitaire Necker-Enfants malades, Université de Paris, Paris, France; Centre Hospitalier Universitaire de Nice (CHU Nice); Centre Pierre et Marie Curie Alger, Algeria; Pole Cardio-vasculaire et pulmonaire CHU Lille; Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille); Centre Hospitalier Universitaire de Bordeaux (CHU Bordeaux); Service Hématologie - IUCT-Oncopole CHU Toulouse; Pôle Biologie CHU Toulouse; Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Pôle IUCT CHU Toulouse; Centre Hospitalier Universitaire de Toulouse (CHU Toulouse); Hopital Saint-Louis AP-HP (AP-HP); Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP); Geneva University Hospitals and Geneva University; none |
| Source: |
ISSN: 0361-8609. |
| Publisher Information: |
CCSD; Wiley |
| Publication Year: |
2025 |
| Collection: |
Université Jean Monnet – Saint-Etienne: HAL |
| Subject Terms: |
elderly patients; allogeneic hematopoietic stem cell transplantation; acute lymphoblastic leukemia; MESH: Humans; MESH: Hematopoietic Stem Cell Transplantation; MESH: Graft vs Host Disease; MESH: France; MESH: Survival Rate; MESH: Disease-Free Survival; MESH: Risk Factors; MESH: Registries; MESH: Precursor Cell Lymphoblastic Leukemia-Lymphoma; MESH: Male; MESH: Female; MESH: Aged; MESH: Middle Aged; MESH: Transplantation Conditioning; MESH: Transplantation; Homologous; [SDV.CAN]Life Sciences [q-bio]/Cancer |
| Description: |
International audience ; ABSTRACT There are very limited data regarding the outcomes of elderly patients with acute lymphoblastic leukemia (ALL) who undergo allogeneic hematopoietic stem cell transplantation (alloHSCT). A total of 316 ALL patients aged ≥ 60 years who underwent alloHSCT between 2010 to 2022 were identified in the SFGM‐TC registry. The primary objective was to evaluate progression‐free survival (PFS), non‐relapse mortality (NRM), relapse incidence (RI), and graft‐versus‐host disease (GvHD)‐free relapse‐free survival (GRFS), as well as their risk factors. The median age was 63.8 years (range 60–75.8), 49.8% of patients had Philadelphia‐positive B‐ALL (Ph + ALL), and 70.9% were in first complete remission (CR1) at transplantation. The donor was an unrelated donor in 52.1%, a matched related donor (MRD) in 26.3%, and a haplo‐identical donor in 17.7%. Reduced‐intensity conditioning (RIC) was administered to 64.6% of patients, while total body irradiation (TBI) was used in 35.8%. The 3‐year overall survival (OS) was 46% (95% CI 40%–53%). The 3‐year PFS, NRM, RI, and GRFS were 41% (95% CI 35%–48%), 23% (95% CI 18%–28%), 36% (95% CI 31%–42%), and 30% (95% CI 25%–37%), respectively. Multivariable analyses confirmed poorer OS and PFS in patients with advanced disease, with an HR of 1.79 (95% CI 1.22–2.64), p = 0.0032. Additionally, the ALL subtype significantly impacted outcomes, with an HR of 1.99 (95% CI 1.42–2.79) for non‐Ph + ALL. This study suggests that alloHSCT is a viable option for elderly ALL patients, as age itself did not impact outcomes. However, advanced disease and non‐Ph + ALL were associated with significantly worse survival. |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| Relation: |
info:eu-repo/semantics/altIdentifier/pmid/40326583; PUBMED: 40326583 |
| DOI: |
10.1002/ajh.27701 |
| Availability: |
https://univ-rennes.hal.science/hal-05305320; https://univ-rennes.hal.science/hal-05305320v1/document; https://univ-rennes.hal.science/hal-05305320v1/file/Chalandon%20-%202025%20-%20Allogeneic%20Hematopoietic%20Stem%20Cell%20Transplantation%20for%20Elderly%20Acute%20Lymphoblastic%20Leukemia%20Patients%20_SFGM-TC%20elderly%20ALL%20alloHSCT%20paper%20revision%20020325%20unmarked%20version.pdf; https://doi.org/10.1002/ajh.27701 |
| Rights: |
https://creativecommons.org/licenses/by-nc/4.0/ ; info:eu-repo/semantics/OpenAccess |
| Accession Number: |
edsbas.41F5953F |
| Database: |
BASE |